Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
A Phase I/II Study of Gleevec/Taxol in Patients With Newly Diagnosed Stage IIIC or IV or Recurrent (Any Stage) Uterine Papillary Serous Carcinoma (UPSC)
Sponsor: M.D. Anderson Cancer Center
Terminated
the study was terminated early due to poor enrollment
Other terminated trials from M.D. Anderson Cancer Center
Other Uterine Cancer trials with similar outcome
A PHASE1/PHASE2 clinical study on Uterine Cancer, this trial is terminated or withdrawn. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 6 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
Status: Completed → Terminated
-
Jun 2018 — Dec 2020 [monthly]
Completed PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Dec 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .